16 hours ago
By James Gallagher
A malaria vaccine with "world-changing" potential has been developed by scientists at the University of Oxford.
The team expect it to be rolled out next year after trials showed up to 80% protection against the deadly disease.
Crucially, say the scientists, their vaccine is cheap and they already have a deal to manufacture more than 100 million doses a year.
The charity Malaria No More said recent progress meant children dying from malaria could end "in our lifetimes".
It has taken more than a century to develop effective vaccines as the malaria parasite, which is spread by mosquitoes, is spectacularly complex and elusive. It is a constantly moving target, shifting forms inside the body, which make it hard to immunise against.
Last year, the World Health Organization gave the historic go-ahead for the first vaccine - developed by pharmaceutical giant GSK - to be used in Africa.
However, the Oxford team claim their approach is more effective and can be manufactured on a far greater scale.
Trial results from 409 children in Nanoro, Burkina Faso, have been published in the Lancet Infectious Diseases. It shows three initial doses followed by a booster a year later gives up to 80% protection.
... The team will start the process of getting their vaccine approved in the next few weeks, but a final decision will hinge on the results of a larger trial of 4,800 children due before the end of the year.
The world's largest vaccine manufacturer - the Serum Institute of India - is already lined up to make more than 100 million doses a year.
Prof Hill said the vaccine - called R21 - could be made for "a few dollars" and "we really could be looking at a very substantial reduction in that horrendous burden of malaria".
By James Gallagher
A malaria vaccine with "world-changing" potential has been developed by scientists at the University of Oxford.
The team expect it to be rolled out next year after trials showed up to 80% protection against the deadly disease.
Crucially, say the scientists, their vaccine is cheap and they already have a deal to manufacture more than 100 million doses a year.
The charity Malaria No More said recent progress meant children dying from malaria could end "in our lifetimes".
It has taken more than a century to develop effective vaccines as the malaria parasite, which is spread by mosquitoes, is spectacularly complex and elusive. It is a constantly moving target, shifting forms inside the body, which make it hard to immunise against.
Last year, the World Health Organization gave the historic go-ahead for the first vaccine - developed by pharmaceutical giant GSK - to be used in Africa.
However, the Oxford team claim their approach is more effective and can be manufactured on a far greater scale.
Trial results from 409 children in Nanoro, Burkina Faso, have been published in the Lancet Infectious Diseases. It shows three initial doses followed by a booster a year later gives up to 80% protection.
... The team will start the process of getting their vaccine approved in the next few weeks, but a final decision will hinge on the results of a larger trial of 4,800 children due before the end of the year.
The world's largest vaccine manufacturer - the Serum Institute of India - is already lined up to make more than 100 million doses a year.
Prof Hill said the vaccine - called R21 - could be made for "a few dollars" and "we really could be looking at a very substantial reduction in that horrendous burden of malaria".
Comment